Clinical Trials Using Disulfiram

Clinical trials are research studies that involve people. The clinical trials on this list are studying Disulfiram. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • Copper Chloride, Disulfiram, and Copper Gluconate in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This phase Ib trial studies the side effects and best dose of copper chloride when given together with disulfiram and copper gluconate in treating patients with castration-resistant prostate cancer that has spread to other places in the body. Copper chloride, disulfiram, and copper gluconate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Duke University Medical Center, Durham, North Carolina

  • Disulfiram and Copper Gluconate with Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma That Can Be Removed by Surgery

    This phase I / II trial studies the side effects and best dose of disulfiram when given together with copper gluconate, radiation therapy, and temozolomide and to see how well they work in treating patients with newly diagnosed glioblastoma that can be removed by surgery. Disulfiram may reduce tumor growth by blocking the activity necessary for tumor growth. Copper gluconate is a dietary supplement that may help disulfiram work better by making the tumor cells more sensitive to the drug. Giving disulfiram and copper gluconate together with radiation therapy and temozolomide may work better in treating patients with glioblastoma.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Disulfiram and Chemotherapy in Treating Patients with Refractory Solid Tumors or Metastatic Pancreatic Cancer

    This partially randomized phase I trial studies the side effects and best dose of disulfiram when given together with chemotherapy in treating patients with a solid tumor that does not respond to treatment (refractory) or pancreatic cancer that has spread to other places in the body (metastatic) and to compare whether disulfiram and chemotherapy may reduce tumor induced muscle loss. Weight loss occurs in pancreatic cancer patients and is common in a multitude of other cancers. Patients with metastatic cancer and weight loss sometimes are not able to receive treatment due to physical weakness or debility. Disulfiram is a potential inhibitor of muscle degradation and may reduce tumor induced muscle wasting. Disulfiram may also help chemotherapy work better by making tumor cells more sensitive to the drug. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving chemotherapy with or without disulfiram is a better treatment for refractory solid tumors or metastatic pancreatic cancer.
    Location: Mayo Clinic, Rochester, Minnesota